Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- Other: Sham
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Allegro Ophthalmics, LLC
- Target Recruit Count
- 42
- Registration Number
- NCT03626636
- Locations
- 🇺🇸
Derek Kunimoto, Phoenix, Arizona, United States
🇺🇸Retina Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Florida Eye Clinic, Altamonte Springs, Florida, United States
A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy
- Conditions
- Non-Proliferative Diabetic Retinopathy
- Interventions
- Drug: 2.0mg Luminate®Drug: 3.0mg Luminate®Drug: 1.0mg Luminate®Other: Balanced Salt Solution for intravitreal injection in 0.10cc
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Allegro Ophthalmics, LLC
- Target Recruit Count
- 105
- Registration Number
- NCT02435862
- Locations
- 🇺🇸
Northern California Retina Vitreous Associates, Mountain View, California, United States
🇺🇸UCI Medical Center, Orange, California, United States
🇺🇸New England Retina Associates, New London, Connecticut, United States
Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Allegro Ophthalmics, LLC
- Target Recruit Count
- 218
- Registration Number
- NCT02348918
- Locations
- 🇺🇸
Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸Retina Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Northern California Retina Vitreous Associates, Mountain View, California, United States
A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion
- Conditions
- Symptomatic Focal Vitreomacular Adhesion
- Interventions
- Drug: 2.0mg of ALG-1001
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Allegro Ophthalmics, LLC
- Target Recruit Count
- 45
- Registration Number
- NCT02153476
- Locations
- 🇺🇸
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸California Retina Consultants, Santa Barbara, California, United States
🇺🇸Center for Retinal and Macular Disease, Winter Haven, Florida, United States
A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Allegro Ophthalmics, LLC
- Target Recruit Count
- 25
- Registration Number
- NCT01749891
- Locations
- 🇲🇽
APEC Hospital La Ceguera, Mexico City, Mexico
- Prev
- 1
- 2
- Next